Meldola

• A Study of Subcutaneous Nivolumab plus Intravenous Ipilimumab and Chemotherapy in Participants with Previously Untreated Metastatic or Recur … Ended recruitment
  2024-520108-25-00 4 2025-11-05 Non-small cell lung cancer (NSCLC)
• Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL … Ended recruitment
  2024-520050-38-00 5 2025-09-18 Extensive stage small cell lung cancer (ES-SCLC). S
• A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended recruitment
  2024-519773-19-00 5 2025-07-31 Gastroesophageal Junction Adenocarcinoma
• Study of Zelenectide Pevedotin in Participants with Advanced Breast Cancer Ended recruitment
  2024-517868-33-00 4 2025-06-12 NECTIN4 Amplified Advanced Breast Cancer
• Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors Ended recruitment
  2024-513307-13-00 4 2025-05-26 Advanced/metastatic solid tumors including gynecological cancers (endo
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended recruitment
  2024-512925-95-00 5 2025-05-16 Advanced/Metastatic Breast Cancer
• A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in Advanced NSCLC (PULMO-01) Ended recruitment
  2024-517741-14-00 9 2025-04-22 advanced non-squamous non-small cell lung cancer (NSCLC)
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended recruitment
  2024-512998-27-00 5 2025-02-21 Non-Small Cell Lung Cancer
• Study on the combination of two immunotherapeutic agents as pre-surgical therapy or definitive treatment in patients with resectable gastric … Ended recruitment
  2024-518842-26-00 4 2025-01-21 Cancer in the stomach or in the junction between the stomach and the o
• A Study to Learn About the Investigational Medicine Called PF-06821497 (mevrometostat) in Men with mCRPC Who Were Previously Treated with Ab … Ended recruitment
  2024-511650-50-00 5 2025-01-17 METASTATIC CASTRATION RESISTANT PROSTATE CANCER
• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemother … Ended recruitment
  2024-511957-23-00 5 2025-01-03 Recurrent or Persistent Endometrial Cancer
• A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing pep … Ended recruitment
  2023-506717-21-00 9 2024-10-02 Breast Cancer
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• A PHASE 1/2 STUDY EXPLORING THE SAFETY AND ACTIVITY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH CAPECITABINE AND BEVACIZUMAB IN METASTATIC … Ended recruitment
  2024-513271-41-00 4 2024-09-16 colorectal metastatic cancer
• A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastat … Ended recruitment
  2023-505655-43-00 7 2024-07-29 Metastatic neuroendocrine prostate cancer
• Single arm phase II study of ctDNA-guided encorafenib plus cetuximab retreatment in patients with BRAF V600E mutated mCRC. BRICKET study Ended recruitment
  2023-509088-26-00 4 2024-07-22 Metastatic colorectal cancer
• A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapse … Ended recruitment
  2023-508426-10-00 3 2024-06-03 Relapsed/Refractory Multiple Myeloma
• A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs ar … Ended recruitment
  2023-508459-37-00 1 2024-05-28 HER2-positive advanced solid tumours
• Comparison between rituximab plus zanubrutinib versus rituximab monotherapy in untreated splenic marginal zone lymphoma patients Ended recruitment
  2023-503755-10-00 5 2024-05-17 Splenic marginal zone lymphoma
• Study with Various Immunotherapy Treatments in Participants With Lung Cancer Ended recruitment
  2022-502916-35-01 4 2024-03-27 Advanced Non-Small Cell Lung Cancer
• Patient Preference for Route of Administration with Intravenous Infusion Switch to Subcutaneous I-O Regimens in Melanoma Ended recruitment
  2023-504515-33-00 4 2024-02-19 Melanoma
• A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended recruitment
  2023-503827-25-01 5 2024-02-16 Non-Small Cell Lung Cancer (NSCLC)
• A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended recruitment
  2023-503288-40-00 5 2024-01-26 Unresectable or Metastatic Melanoma
• A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma … Ended recruitment
  2023-503575-21-00 5 2024-01-23 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Showing 241–264 of 447 trials